(Alliance News) - Arix Bioscience PLC on Tuesday said Naseem Amin has been appointed as a non-executive director with immediate effect.
In addition, Arix said Franz Humer will be retiring from the board on the same date.
The investment firm said Amin will be a member of the Remuneration Committee.
Amin is currently chief executive of GMP-Orphan and a venture partner at Advent Life Sciences. He previously was chief scientific officer of FTSE 100-listed medical equipment firm Smith & Nephew PLC.
Arix shares were trading 2.5% lower in London on Tuesday afternoon at 112.10 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.


Smith & Nephew PLC - Watford, England-based medical devices maker - Announces the completion of the first clinical cases performed using the next gene...


(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday.


(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and Friday:


Arix Bioscience PLC - London-based venture capital firm focused on biotechnology companies - Shares suspended from the London Stock Exchange amid the ...


RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Says it completed on Friday its previously announ...


Arix Bioscience PLC - London-based venture capital firm investing in "breakthrough" biotechnology companies - Expects USD18.6 million net proceeds fro...


(Alliance News) - RTW Biotech Opportunities Ltd on Wednesday said it has agreed to acquire all the assets of fellow London listing Arix Bioscience PLC...


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and Tuesday and not separat...


(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review d...